Key result
This review highlights evolving pharmacological therapies and devices for the management of chronic refractory angina, which affects an estimated 5-15% of patients with chronic angina.
This review summarizes evolving pharmacological and device-based therapies for the management of chronic refractory angina.
May expand options for refractory angina; leaves open the need for RCTs to confirm benefits.
Chronic refractory angina is a term used to describe patients who, despite optimal medical therapy, have both angina and objective evidence of ischaemia. It is estimated that 5-15% of the 12 million patients with chronic angina in the US meet the criteria for having refractory angina. This review focuses on the following evolving pharmacological therapies for chronic refractory angina: L-arginine, ivabradine, ranolazine, nicorandil and trimetazidine. Evolving devices and invasive procedures including enhanced external counterpulsation, spinal cord stimulation, and transmyocardial revascularisation are also briefly discussed.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2006) conducted a review in Chronic refractory angina. Evolving pharmacological therapies and devices was evaluated. This review highlights evolving pharmacological therapies and devices for the management of chronic refractory angina, which affects an estimated 5-15% of patients with chronic angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: